SpaceX's Lockup Test Passed, But the 2026 Issuance Wave Is Just Beginning

The most telegraphed selling event of 2026 turned into a buying opportunity. On August 6, the first post-IPO lockup restrictions on SpaceX (SPCX) expired, freeing 911 million shares — roughly 7% of shares outstanding and 43% more than the 639 million shares sold in the record June IPO. Wall Street had spent weeks bracing for an insider fire sale on a stock that had already fallen more than 50% from its mid-June peak of $225. Instead, the stock closed up 6.1% that day^[1], with more than 255 million shares changing hands — the heaviest volume since the IPO’s first week of trading.

As of today’s close, SPCX sits at $146.15, up 9.65% on the session^[2], a striking recovery from the $108 lows of early August. The lockup that was supposed to break the stock instead marked its bottom.

What the lockup rally actually means

The dynamic was textbook event-driven mechanics. D.A. Davidson analyst Gil Luria noted that the stock had slid almost every day for three to four weeks in anticipation of the unlock — from roughly $152 on July 9 down toward $110 — as short-term traders sold ahead of the supply event and planned to cover once the selling pressure materialized^[3]. When the expected torrent of insider selling did not arrive, those shorts had to buy back. Morgan Stanley and others had used the phrase “generational compounder” to describe SpaceX, and the lockup expiry gave long-term institutional buyers the liquidity they had been waiting for. Instead of chasing a thin float, large funds could match block trades through brokers at the liquidity event itself.

Tigress Financial Partners’ chief investment officer Ivan Feinseth framed it as a healthy handoff: “a largely technical event that accelerates the transition of ownership from insiders to a deeper, more stable public float, rather than a signal of deteriorating fundamentals”^[3]. Underneath the price noise, SpaceX reported roughly 92% year-over-year revenue growth in its first earnings disclosure, though capital expenditures came in at more than twice revenue — a gap that explains why the stock had been under pressure even before the lockup narrative took hold.

But the lockup calendar is far from over. Another 319 million shares could unlock on August 20, followed by roughly 700 million in September and a similar tranche in October^[4]. Elon Musk’s own holdings — more than 6 billion shares — remain locked until June 2027. The staggered schedule means the float will keep expanding through the fall, and each tranche is a separate test of whether the buyer base absorbs the incremental supply without flinching. The first test passed. The next three are queued.

The issuance wave in numbers

Step back from any single stock and the 2026 picture is historic. The SEC reported 99 IPOs raising over $22 billion in Q1 2026, an 86% increase in proceeds versus Q1 2025^[5]. Q2 was even larger: 48 IPOs raised $104.8 billion, the largest quarter for US listings on record, with SpaceX alone accounting for $75 billion of that total^[6]. US equity capital markets proceeds topped $120 billion through the first half — the strongest H1 pace since 2021 — with follow-ons contributing $42 billion in Q1 and convertible issuance running at roughly double last year’s pace at $34 billion through April^[7].

UBS projects IPO issuance on track to reach $200-350 billion this year, with secondary offerings potentially exceeding $400 billion — both record highs in absolute dollar terms^[8]. The Federal Reserve’s flow-of-funds data showed $389 billion in new equities hitting the market in Q1 2026 alone, a figure that would have been the largest single quarter of issuance since 1996 were it not for the COVID-era spike in early 2021^[9].

EY’s Q2 2026 Global IPO Trends report described the first-half activity as setting the stage for “what could be a historic 2H 2026,” while cautioning that execution windows may be episodic and shaped by mega-IPOs and geopolitics^[10].

Can the market absorb it?

The supply question has a reasonably reassuring answer at the aggregate level, though the distribution matters more than the total. UBS makes three structural points: first, issuance relative to the roughly $72 trillion US equity market capitalization is only slightly above the long-term average as a percentage of free float — heavier issuance represents a return to normal, not an anomaly^[8]. Second, US share buybacks totaled $1.2 trillion over the past 12 months, meaning net equity supply could still shrink even as gross issuance hits records. Third, academic literature finds no consistent relationship between IPO activity and forward market returns; the stronger historical pattern is that issuance is a coincident indicator that rises when markets are strong, not a leading indicator that predicts declines.

Goldman Sachs arrived at a similar conclusion: “Record U.S. equity issuance will not derail the bull market in 2026,” adding that “supply remains modest relative to the size of the equity market”^[9].

The concentration risk, however, is real. As Axios reported, the burst of new stock is overwhelmingly AI-related — both in the companies coming public and in the follow-on issuance from incumbents like Alphabet and Oracle that are raising cash for AI infrastructure buildout^[9]. ArcStone identified roughly $725 billion in 2026 hyperscaler capital expenditure as the force reshaping the entire ECM landscape, with power — not compute — as the binding constraint^[7]. If AI sentiment shifts, the thematic concentration that makes this issuance wave coherent becomes the same concentration that makes it fragile.

The pipeline behind the pipeline

The summer IPO market is entering its seasonal wind-down. Renaissance Capital described the current week — led by Londian Wason New Energy Tech (FOIL), a Chinese copper-foil supplier raising $75 million at a $1.6 billion market cap — as “last call for the summer IPO market”^[11]. In a typical year, companies have one more week to launch offerings before the calendar goes quiet until September.

What follows the summer lull is where the real supply test begins:

Six of these entries rest on press reporting rather than public filings, and confidential filings carry no tested valuations. But the direction of travel is clear: Anthropic is the next mega-IPO likely to price, and its October window will set the AI valuation comp that every candidate behind it is measured against. If Anthropic prices well, OpenAI’s calculus may shift back toward 2026. If it stumbles, the pipeline narrows.

What the secondary market tells us

The pre-IPO market has been reordering itself around the IPO window rather than waiting for it. Companies are using semiannual buybacks, tender offers, and secondary platforms to deliver liquidity to employees and early investors without going public^[12]. SpaceX itself ran semiannual buyback programs for a decade before listing, and former employees told Fortune that each round was oversubscribed — employees who asked to sell were cut back to single-digit percentages of their positions^[3]. That culture of partial liquidity may explain why the lockup expiry did not produce a rush for the exits: many insiders had already taken chips off the table across multiple prior liquidity events.

Meanwhile, sponsor-driven follow-ons are doing the heaviest lifting. ArcStone estimates that roughly 67% of March follow-on volume was sponsor-led, as vintage 2017-2020 private equity funds press for LP liquidity^[7]. The $1.1 trillion in buyout-fund dry powder backing these exits will eventually need to recycle, and the IPO window is the primary valve.

What to watch next

• August 20 lockup tranche (SpaceX): 319 million additional shares unlock. The first tranche’s 6% rally was partly a short-covering artifact; the second tranche tests whether organic demand, not just event-driven flow, is absorbing supply.
• SpaceX Cursor acquisition close: The $60 billion deal for Cursor is expected to close this quarter^[4]. How the market prices the combined entity will set a reference for AI-infrastructure M&A valuations.
• Anthropic October IPO: The next mega-deal in the queue. Its pricing will determine whether the AI-IPO window stays open through year-end or narrows to a trickle. A strong print likely pulls OpenAI’s timeline forward; a weak one pushes the entire pipeline into 2027.
• September and October lockup tranches (SpaceX): Roughly 700 million shares each month. Each is a discrete liquidity event that large institutional buyers may wait for rather than chase in the open market.
• VIX and rates: ArcStone noted convertible issuance has been taking advantage of a VIX near 16.76 and a 10-year at 4.59%^[7]. If either backs up, the favorable pricing window for converts and follow-ons tightens, and the ECM calendar compresses.
• Renaissance IPO Index performance: Up 18.6% YTD versus the S&P 500’s 13.4%^[11]. If newly public companies continue outperforming, the signal to private companies is that the window is open. If that spread reverses, expect more confidential filings to stay confidential.

The base case is constructive: record issuance absorbed by a market that is, in aggregate, large enough to handle it, with buybacks offsetting gross supply. I’d put the probability of the IPO market remaining broadly open through year-end at roughly 65%, with a 20% chance of an episodic freeze (an Anthropic stumble or geopolitical shock narrowing the window sharply) and a 15% chance of a broad-based reopening that exceeds even the current pace. The lockup rally at SpaceX was the market’s first answer to the supply question. The fall will provide the second.